MBX Biosciences, Inc./$MBX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About MBX Biosciences, Inc.
MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include MBX 2109, MBX 1416, and MBX 4291.
Ticker
$MBX
Sector
Health
Primary listing
Employees
43
Headquarters
Website
MBX Metrics
BasicAdvanced
$372M
-
-$2.89
-
-
Price and volume
Market cap
$372M
52-week high
$15.94
52-week low
$4.81
Average daily volume
470K
Financial strength
Total debt to equity
0.055
Profitability
EBITDA (TTM)
-86.269
Management effectiveness
Valuation
Price to book
1.58
Price to tangible book (TTM)
1.58
Growth
Earnings per share change (TTM)
-92.84%
Bulls say / Bears say
MBX Biosciences' lead candidate, MBX 2109, is in Phase 2 trials for chronic hypoparathyroidism, addressing a significant unmet medical need. (stockanalysis.com)
Analysts have set an average 12-month price target of $37.40 for MBX, indicating a potential upside of approximately 199%. (stockanalysis.com)
The company recently submitted an IND for MBX 4291, a GLP1/GIP receptor co-agonist prodrug targeting obesity, expanding its pipeline into a lucrative market. (mbxbio.com)
MBX reported a net loss of $73.47 million over the trailing twelve months, highlighting ongoing financial challenges. (stockanalysis.com)
The stock has experienced significant volatility, with a 52-week range between $4.81 and $27.50, indicating potential instability. (stockanalysis.com)
As a clinical-stage company, MBX faces inherent risks associated with drug development, including potential trial failures and regulatory hurdles. (stockanalysis.com)
Data summarised monthly by Lightyear AI. Last updated on 10 Jul 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for MBX Biosciences, Inc. stock?
MBX Biosciences, Inc. (MBX) has a market cap of $372M as of August 08, 2025.
What is the P/E ratio for MBX Biosciences, Inc. stock?
The price to earnings (P/E) ratio for MBX Biosciences, Inc. (MBX) stock is 0 as of August 08, 2025.
Does MBX Biosciences, Inc. stock pay dividends?
No, MBX Biosciences, Inc. (MBX) stock does not pay dividends to its shareholders as of August 08, 2025.
When is the next MBX Biosciences, Inc. dividend payment date?
MBX Biosciences, Inc. (MBX) stock does not pay dividends to its shareholders.
What is the beta indicator for MBX Biosciences, Inc.?
MBX Biosciences, Inc. (MBX) does not currently have a Beta indicator.